Users are celebrating Chai Discovery's $400M Series C at $3.8B valuation because they see the funding as massive progress for AI-driven drug design and want to cheer on the team.
Based on 31 visible X reactions from 33 accounts.
Ask a question below.
Published answers will appear here.
@jackdent @IndexVentures @kleinerperkins @sequoia @_DimensionCap @m_delamerced @nytimes this is massive! can't wait to see the impact on drug discovery, congrats to the team!
@jackdent @IndexVentures @kleinerperkins @sequoia @_DimensionCap @m_delamerced @nytimes woohoo!! awesome news! congrats Jack! 👏👏👏👏👏
@jackdent @zavaindar @IndexVentures @kleinerperkins @sequoia @_DimensionCap @m_delamerced @nytimes Wonderful! Congratulations!
@jackdent @IndexVentures @kleinerperkins @sequoia @_DimensionCap @m_delamerced @nytimes Congrats team!! 💚
Thanks to all our investors for sharing our conviction. AI drug discovery has moved from promise to deployment, and Chai’s models are already unlocking progress for partners. Read more in @m_delamerced's reporting in the @nytimes: https://www.nytimes.com/2026/07/14/business/dealbook/chai-discovery-ai-drug-development.html
@jackdent @IndexVentures @kleinerperkins @sequoia @_DimensionCap @m_delamerced @nytimes this is massive! can't wait to see the impact on drug discovery, congrats to the team!
@jackdent @IndexVentures @kleinerperkins @sequoia @_DimensionCap @m_delamerced @nytimes woohoo!! awesome news! congrats Jack! 👏👏👏👏👏
@jackdent @zavaindar @IndexVentures @kleinerperkins @sequoia @_DimensionCap @m_delamerced @nytimes Wonderful! Congratulations!
@jackdent @IndexVentures @kleinerperkins @sequoia @_DimensionCap @m_delamerced @nytimes Congrats team!! 💚
Thanks to all our investors for sharing our conviction. AI drug discovery has moved from promise to deployment, and Chai’s models are already unlocking progress for partners. Read more in @m_delamerced's reporting in the @nytimes: https://www.nytimes.com/2026/07/14/business/dealbook/chai-discovery-ai-drug-development.html
Users are celebrating Chai Discovery's $400M Series C at $3.8B valuation because they see the funding as massive progress for AI-driven drug design and want to cheer on the team.
Based on 31 visible X reactions from 33 accounts.
Ask a question below.
Published answers will appear here.